GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.

High-fiber foods, such as vegetables and whole grains, can also reduce stomach acid. Acid reflux happens when stomach acid flows backward into the esophagus, causing heartburn. This burning pain ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...

Acid reflux or heartburn is technically known as gastroesophageal ... H-2-receptor blockers that can decrease acid production in the stomach for up to 12 hours, such as ranitidine (Zantac), and lastly ...

Famotidine also treats gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the ... of this medicine does not contain ranitidine, a medicine that was withdrawn ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...